Johnson & Johnson OKs $2B LifeScan sale to Platinum Equity

Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer of more than $2 billion from private equity shop Platinum Equity for its LifeScan blood glucose monitoring business as it moves toward the exit in the diabetes market. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to outright shutter the Animas insulin pump subsidiary. Get the full story at our sister site, Drug Delivery Business News. The post Johnson & Johnson OKs $2B LifeScan sale to Platinum Equity appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Diabetes Mergers & Acquisitions Wall Street Beat johnsonandjohnson LifeScan Inc. Source Type: news